Why would anyone take on what is arguably the most complex of the complex, chronic diseases?

That’s the question Cort Johnson, founder of leading patient advocacy site Health Rising, asks in his latest feature about our work in ME/CFS and Long COVID.

➡️ www.healthrising.org/blog/2025/10...

After a whirlwind few weeks welcoming new baby to the world, it was great to join the @precisionlife.bsky.social team at the Victoria House launch – home to our new London offices.

Excited for what's next as we advance precision medicine to improve health for billions living with chronic diseases.

How Do You Sell What Never Happens? The Invisible Power of Preventative Health How do you convince people to care more about something they might avoid?

We know prevention saves lives and money. So why is it still such a hard sell?

From climate change to COVID, we keep ignoring prevention until crisis hits.

My latest Signal explores why - and how we can change the story for preventative health.

www.noahkonig.com/p/how-do-you...

The New Rules of Life Science Marketing: How to Lead in the Age of AI I’ve been in life science marketing for over 15 years, and I can say confidently that we’re in the middle of a seismic transformation.

The rules of the game in life sciences marketing are being rewritten, and those who don’t adapt risk being left behind.

For fellow marketers & communicators in life sciences, here's how we keep up:

open.substack.com/pub/noahkoni...

Pharma faces a $200B patent cliff by 2030 – one of the sharpest in history.

It’s not just about lost revenue, but the future of discovery & patient access.

My take on how precision medicine could turn crisis into opportunity:
🔗 noahkonig.substack.com/p/beyond-the...

Chronic diseases overwhelm health systems, yet most lack accurate risk prediction or effective treatment. In a new insight article, our CEO explores how mechanism-based precision medicine can change that.

🔗 precisionlife.com/future-now

#PrecisionMedicine
#PrecisionLife

New in Bio-IT World: how PrecisionLife is enabling mechanism-based precision medicine for complex diseases like ME/CFS, long COVID, ALS & endometriosis.

Read the article: www.bio-itworld.com/news/2025/06...

#precisionmedicine #biomarkers #PrecisionLife

Rowan Gardner (@rowanbio.bsky.social) joins global leaders at Oxford Nanopore’s (@nanoporetech.com) Informatics Day tomorrow to discuss how AI and genomics can unlock new insights in complex disease biology.

🔗 nanoporetech.com/about/events...

#LondonCalling25 #Genomics #AI #PrecisionMedicine

Looking forward to this one.

Excellent speakers, the latest #MECFS discoveries, and a live Q&A with patient and public involvement representatives - all moderated by the brilliant Sonya Chowdhury.

📅 Register now for June 6 →

Heading to #WCE2025?

We'll be there sharing new insights into genetic risk, patient stratification & diagnostic tools for #endometriosis and #womenshealth.

Come meet us in Sydney & explore the future of #precisionmedicine.

🔗 precisionlife.com/news-and-eve...

📢 This #WorldMEDay, we’re proud to share real progress towards better outcomes for people living with ME/CFS and Long COVID.

Genetic Risk Factors for Long COVID Reproduced Across Populations | PrecisionLife PrecisionLife study confirms reproducible genetic markers for long COVID in diverse cohorts, advancing diagnostic and treatment strategies for the disease.

PrecisionLife & Metrodora confirm the first reproducible genetic signatures for #LongCOVID across ancestries. Just in time for #WorldMEDay, this marks major progress for patients with complex chronic conditions.

🔗 Read: precisionlife.com/publication-...

#PrecisionMedicine #MECFS #Genomics

Reproducibility of genetic risk factors identified for long COVID using combinatorial analysis across US and UK patient cohorts with diverse ancestries - Journal of Translational Medicine Background Long COVID is a major public health burden causing a diverse array of debilitating symptoms in tens of millions of patients globally. In spite of this overwhelming disease prevalence, stagg...

Very proud of our team @precisionlife.bsky.social and our partners today translational-medicine.biomedcentral.com/articles/10....
Reproducing insights across populations
🧬🖥️

We’re heading to Abu Dhabi Global Health Week to share how PrecisionLife is enabling th eprediction and prevention of major chronic diseases with groundbreaking insights into the mechanisms driving complex conditions. Let’s connect. 🌍
🔗 precisionlife.com/news-and-eve...
#ADGHW2025 #PrecisionMedicine

Ending the Endometriosis Odyssey A single buccal swab could accelerate diagnosis, ending years of uncertainty for patients

🧬 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗯𝗲𝘁𝘁𝗲𝗿 𝘄𝗮𝘆𝘀 𝘁𝗼 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗲 𝗮𝗻𝗱 𝘁𝗿𝗲𝗮𝘁 𝘄𝗼𝗺𝗲𝗻 𝘄𝗶𝘁𝗵 𝗲𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗼𝘀𝗶𝘀 🧬

Our Product Strategy Lead Hannah Bibby spoke to The Pathologist about TRANSCEND – using multi-omics + AI to uncover the biology and enable better diagnosis + treatment.

Read the Q&A: thepathologist.com/issues/2025/...

It’s #WorldHealthDay 🌍

Chronic diseases cause 80% of healthcare costs & affect billions.

At PrecisionLife we’re working to predict, treat & prevent them—improving health outcomes & reducing cost of care so people can live longer, healthier lives.

🔗 precisionlife.com/healthspan

#PrecisionMedicine

PrecisionLife Co-founder and Chief Business & Investment Officer, Rowan Gardner @rowanbio.bsky.social, will be chairing the sold out 𝗙𝗶𝗻|𝗧𝗲𝗰𝗵|𝗕𝗶𝗼 𝗮𝘁 𝗖𝗮𝗻𝗮𝗿𝘆 𝗪𝗵𝗮𝗿𝗳 event this evening.

For more details about this and future events, visit: level39.co/event/fintec...

Hi - a fair question and I can share that a reproduction study is underway for ME/CFS based on DecodeME data as part of the LOCOME project. Details of PrecisionLife's research and progress in ME/CFS & long COVID is linked to here, incl full study manuscripts: bsky.app/profile/prec... hope this helps

Very pleased to see this study which demonstrates the value of the AllofUs population in enabling molecular etiology of disease to be evaluated in diverse genetic ancestries.

Long Covid is estimated to have a Health + Socioeconomic Cost / Year of $1Trillion dollars.

ALS/MND Natural History Consortium Annual Meeting PrecisionLife CEO, Steve Gardner, presents AI-led Precision Medicine, Drug Repurposing and Rapid Validation Strategies for ALS

We're honored that our CEO, Steve Gardner, will deliver the keynote lecture at next week's ALS/MND Natural History Consortium Annual Meeting in Boston.

For details, see:
🔗 precisionlife.com/news-and-eve...

#ALS #MND #PrecisionMedicine #Neuroscience

PrecisionLife awarded €2.5M to develop and clinically validate a rapid, non-invasive precision medicine test for endometriosis, to identify at-risk patients, accurately triage and treat.

The mission is clear:
✔️ Triage & refer faster
✔️ Treat more effectively
✔️ Improve millions of lives

More below ⬇️

This latest publication from @precisionlife.bsky.social will no doubt be of interest @erictopol.bsky.social.

#MECFS #LongCOVID #ChronicDiseases #PrecisionMedicine

🔗 www.sciencedirect.com/science/arti...

The implications and potential for Actively Protective Biology in preventing the onset and progression of complex diseases are HUGE for precision medicine, healthy aging, and major chronic diseases like diabetes, dementia, ME/CFS and long COVID.

Full paper at: www.sciencedirect.com/science/arti...

💡 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘆𝗼𝘂 𝗴𝗲𝘁 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝘁 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁 𝘁𝗶𝗺𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝗰𝗼𝗺𝗽𝗹𝗲𝘅 𝗮𝗻𝗱 𝗰𝗼𝘀𝘁𝗹𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀?

Hear how #precisionmedicine is driving innovation in #healthcare, #diagnostics and #bio.

🎙️ precisionlife.com/podcast-the-...

Actively Protective Combinatorial Analysis: a Scalable Novel Method for Detecting Variants that Contribute to Reduced Disease Prevalence in High-Risk Individuals We present a novel method for routinely identifying disease resilience associations that offers powerful insights for the discovery of a new class of disease protective targets. We show how this can be used to identify mechanisms in the background of normal cellular biology that work to slow or stop progression of complex, chronic diseases. Actively protective combinatorial analysis identifies combinations of features that contribute to reducing risk of disease in individuals who remain healthy even though their genomic profile suggests that they have high risk of developing disease. These protective signatures can potentially be used to identify novel drug targets, pharmacogenomic and/or therapeutic mRNA opportunities and to better stratify patients by overall disease risk and mechanistic subtype. We describe the method and illustrate how it offers increased power for detecting disease-associated genetic variants relative to traditional methods. We exemplify this by identifying individuals who remain healthy despite possessing several disease signatures associated with increased risk of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or amyotrophic lateral sclerosis (ALS). We then identify combinations of SNP-genotypes significantly associated with reduced disease prevalence in these high-risk protected cohorts. We discuss how actively protective combinatorial analysis generates novel insights into the genetic drivers of established disease biology and detects gene-disease associations missed by standard statistical approaches such as meta-GWAS. The results support the mechanism of action hypotheses identified in our original causative disease analyses. They also illustrate the potential for development of precision medicine approaches that can increase healthspan by reducing the progression of disease. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study did not receive any funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: UK Biobank has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval, and researchers do not require separate ethical clearance and can operate under this RTB approval. Ethical approval for the project MinE dataset is described in detail in Van Rheenen et al. (2018) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present work are contained in the manuscript

Enjoying the positive feeling of @precisionlife.bsky.social team's Active Protective Biology manuscript being accepted for publication.

Applications of this approach include novel drug targets to avoid disease onset and optimal inclusion critera in trials

Preprint here doi.org/10.1101/2024...

Delighted to be working alongside Bill at @precisionlife.bsky.social as we enable the prediction and prevention of chronic diseases that affect over 5 billion patient lives.

precisionlife.com/news-and-eve...

Fierce Biotech's Rotten Tomatoes of 2024 Biotech experienced a year of mixed fortunes in 2024. | Fierce Biotech recounts the biggest biotech blunders and one inspiring intervention in the 2024 edition of Rotten Tomatoes.

It's that time of year again - Biotech's Rotten Tomatoes of 2024

www.fiercebiotech.com/biotech/fier...

From @jameswaldron.bsky.social

AbbVie buys Roche spinout Nimble Therapeutics for $200M AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble Ther...

AbbVie's Christmas shopping continues with another acquisition

www.fiercebiotech.com/biotech/abbv...

Eleven clinical trials that will shape medicine in 2025 - Nature Medicine Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health.

Eleven clinical trials that will shape medicine in 2025 www.nature.com/articles/s41...

Insightful conversation between CEO's of companies leading the way in #precisionmedicine and a message of genuine hope for the future of healthcare to improve patient outcomes and reduce the global burden of complex diseases.

Spare 30-minutes to listen 🎧

precisionlife.com/podcast-over...